Screener / SEC EDGAR /CIK 0001639691 /10-K filed Feb 25, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

LivaNova PLC LIVN

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of LIVN's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Sep 18, 2018
Questions asked 43 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 6 UPLOAD
  2. 2. Questions in them 43 numbered comments
  3. 3. Company replies 7 CORRESP
  4. 4. Reviews closed 3 of 4 closing letter

Half the closed reviews took 29 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2017

2018-09-18 to 2018-10-26 · 2 questions · 1 letter from the SEC, 2 from the company
Review closed 2018-10-26
Non-GAAP measures
After reviewing your response to these comments, we may have additional comments. Exhibit 99.1, page 3
SEC asked (1)
We note that you present the forward looking non-GAAP measure adjusted diluted earnings per share without providing the reconciliation to the most directly comparable GAAP financial measure or the statement that providing such reconciliation requires unreasonable efforts.
Rest of the question

Refer to Item 10(e)(1)(i)(B) of Regulation S-K and the guidance in Question 102.10 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures and revise your future filings to provide the required information.

LIVN answered
The Company acknowledges the Staff’s comment noting that reconciliation to the most directly comparable GAAP financial measure for adjusted diluted earnings per share for 2018, a forward-looking non-GAAP financial measure, is not presented.

LivaNova PLC,

T +44 (0) 20 33250660

Registered in England and Wales

Registered No.
Rest of the answer

09451374 www.livanova.com

20 Eastbourne Terrace

London W2 6LG

United Kingdom

In future filings of our Forms 8-K and Exhibits 99.1, we will add the following disclosure:

“LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net sales growth projections are estimated on a constant currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted tax rate and adjusted diluted earnings per share guidance exclude other items such as, but not limited to, changes in fair value of contingent consideration arrangements, asset impairment charges and product remediation costs that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for constant currency net sales, non-GAAP adjusted tax rate and adjusted diluted earnings per share are net sales, the effective tax rate, and earnings per share, respectively. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of contingent consideration arrangements, product remediation costs, asset impairment charges and the tax impact of the items above and the tax impact of tax law changes or other tax matters. Accordingly, reconciliations to the most directly comparable forward-looking GAAP financial measures are not available without unreasonable effort.”

Read in the reply
In its next report

First report after the company's reply of Sep 24, 2018: 10-Q filed Nov 1, 2018 ↗, against the 10-Q filed Aug 2, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

After reviewing your response to these comments, we may have additional comments. Exhibit 99.1, page 3
SEC asked (2)
On pages 13-16 you present the reconciliations of your non-GAAP measures to the most directly comparable GAAP measures in the form of a full non-GAAP income statement, a presentation that gives greater prominence to the non-GAAP measures.
Rest of the question

Refer to the first bullet point within Question 102.10 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures and revise your presentation in future filings accordingly. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

LIVN answered
The Company acknowledges the Staff’s comment. We believe the presentation of reconciliations of our non-GAAP measures to the most directly comparable GAAP measures in the form of a full non-GAAP income statement does not place undue prominence on the non-GAAP information. The GAAP income statement is presented on a standalone basis prior to the reconciliation of our non-GAAP measures to the directly comparable GAAP measures. We believe this demonstrates greater prominence over the non-GAAP financial measures.
Rest of the answer

While Question 102.10 states that generally, a full non-GAAP income statement causes non-GAAP measures to be more prominent, various users of our financial statements find the current presentation of our GAAP and non-GAAP results to be informative and transparent. Prior to 2018, the Company presented a summarized reconciliation of non-GAAP measures to the most directly comparable GAAP measures, and the Company frequently received requests from financial statement users to provide further detail and transparency with respect to the reconciling items in each income statement line item.

In summary, we respectfully request the Staff accept our proposal to continue the use of the reconciliations of our non-GAAP measures in the form of a full non-GAAP income statement, always to be presented after the more prominent, standalone GAAP income statement.

Read in the reply
In its next report

First report after the company's reply of Sep 24, 2018: 10-Q filed Nov 1, 2018 ↗, against the 10-Q filed Aug 2, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: company letter, Oct 25, 2018, closing letter, 2018-10-26

Form 10-K for the Fiscal Year Ended December 31, 2016

2017-06-20 to 2017-07-11 · 4 questions · 1 letter from the SEC, 1 from the company
Review closed 2017-07-11
RevenueSegmentsResults discussion (MD&A)Legal and contingenciesIncome taxes
Management Discussion and Analysis of Financial Condition and Results of Operations · Business Franchises, page 50
SEC asked (1)
We note the significant differences in revenues and income from operations of your three segments on page F-56. In future filings, to enhance an investor’s understanding of your results of operations, please consider providing a discussion of your segment results in addition to your consolidated results. Please refer to Item 303(a) of Regulation S-K and FRC 501.06.a regarding segment analysis.
LIVN answered
The Company acknowledges the Staff’s comment and will provide a discussion of segment results, including a discussion of our segments’ net sales and operating income, in future filings to enhance an investor’s understanding of our results of operations, beginning with the Form 10-Q for the quarterly period ending June 30, 2017.

LivaNova PLC,
Read in the reply
In its next report

First report after the company's reply of Jun 29, 2017: 10-Q filed Aug 9, 2017 ↗, against the 10-Q filed May 3, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 2 – Basis of Presentation, Use of Accounting Estimates and Significant Accounting Policies · Comprehensive Income and Foreign Currency Translations, page F-1 7
SEC asked (2)
We note your significant foreign operations and that you are a United Kingdom corporation reporting your financial statements in U.S. dollars. In future filings, please revise this note to disclose your functional currency as well as those of your significant foreign subsidiaries.
Rest of the question

Disclose your policy for determining the functional currency of foreign entities, and describe your accounting for foreign currency transactions – i.e., transactions denominated in a currency different from the functional currency. In addition, disclose your policy for foreign currency translation. Refer to ASC 235-10-501, ASC Topic 830 and FRC 501.09.b.

LIVN answered
The Company acknowledges the Staff’s comment and will revise the Comprehensive Income and Foreign Currency Translations section of our Basis of Presentation, Use of Accounting Estimates and Significant Accounting Policies footnote in future filings to include the items noted in the Staff’s comment, beginning either with the Form 10-Q for the quarterly period ending June 30, 2017, to the extent the disclosures are believed to be material, or with the Form 10-K for the year ending December 31, 2017.
Read in the reply
In its next report

First report after the company's reply of Jun 29, 2017: 10-Q filed Aug 9, 2017 ↗, against the 10-Q filed May 3, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 18 – Commitments and Contingencies, page F-35
SEC asked (3)
Please revise your disclosure of the Baker, Miller et al matter on page F-36 in future filings to provide all the information required by ASC 450-20-50-4, including an estimate of the possible loss or a clear statement that such an estimate cannot be made.
LIVN answered
The Company acknowledges the Staff’s comment and will revise its disclosure of the Baker, Miller et al matter in future filings to include all the information required by ASC 450-20-50-4 based on an evaluation of the specific facts and circumstances in existence at the time of the filing, beginning with the Form 10-Q for the quarterly period ending June 30, 2017.
Read in the reply
In its next report

First report after the company's reply of Jun 29, 2017: 10-Q filed Aug 9, 2017 ↗, against the 10-Q filed May 3, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 22 – Income Taxes, F-50
SEC asked (4)
On page F-52 you include a ‘gain on sale of intellectual property’ as a deferred tax liability while on page F-25 you show an asset titled ‘taxes payable on inter-company transfers of property’. To help us better understand your disclosure, including the discussion on page F-53, please address the following:  Clearly describe to us the transaction that resulted in the items being reflected on your balance sheet.
Rest of the question

 Describe to us your accounting for the transaction, including the accounting literature on which you relied and provide sample journal entries.  Explain why a taxes payable account is being reported as an asset.

LIVN answered
In 2016, LivaNova made the decision to centralize the management and economic ownership of Intellectual Property for its manufacturing technology and product patents (“IP”) in the United Kingdom (“UK”) where LivaNova PLC is domiciled. On June 1, 2016, LivaNova IP Limited (“IP Co.”), a limited company organized under the laws of England and Wales and a wholly owned subsidiary of LivaNova PLC, obtained all beneficial rights and economic ownership in and to the IP of a wholly owned U.S.
Rest of the answer

subsidiary of LivaNova PLC, in exchange for the principal amount of $417.5 million, payable annually in eight equal cash installment payments of $52.2 million on December 31st of each year. This amount is taxable income to the U.S. subsidiary in the year in which each installment payment is received.

Describe to us your accounting for the transaction, including the accounting literature on which you relied and provide sample journal entries.

Company Response:

The intercompany sale of assets between related parties in different jurisdictions may be a taxable event for income tax purposes in the country of sale. However, as provided under ASC 810-10-45-1 and ASC 740-10-25-3(e), the income tax provision effects from such a sale are deferred in preparation of the consolidated financial statements through the establishment of a prepaid tax asset. A transaction that is an intra-entity sale or transfer of either tangible or intangible assets qualifies for deferral treatment for financial statement purposes.

ASC 810-10-45-8 provides that no income tax effect should be recognized in earnings due to an intra-entity transfer between affiliated entities until the asset leaves the reporting group (as an example through sale to an unrelated third party) or is depreciated / amortized or impaired by the buying entity.

Upon the sale to IP Co, a deferred tax liability was created in the U.S. selling entity for the future tax impact of the gain with an offset to deferred tax expense. As a result, an ASC 810-10-45-8 Asset was also created effectively reversing the deferred tax expense recognized on the separate financials of the U.S. subsidiary. Thus, there was no impact on income tax expense on the date of the transaction. As payments are made to the U.S. subsidiary, the deferred tax liability will be reduced and a current payable will be established. The tax consequences will be recognized each year as the ASC 810-10-45-8 Asset is amortized to income tax expense over the IP’s estimated useful life of eight years.

The following journal entries were recorded during the year ended December 31, 2016 (in millions):

Dr.

Deferred Tax Expense

$

155.6

Cr.

Deferred Tax Liability

Entry #1 Description: To record the deferred tax liability on the date of the IP sale (June 1, 2016).

Taxes Payable on I/C Transfer (ASC 810-10-45-8 Asset) - Current

19.4

Taxes Payable on I/C Transfer (ASC 810-10-45-8 Asset) - Non-Current

136.2

Entry #2 Description: To set up the ASC 810-10-45-8 Asset to defer the income tax effect of the IP sale (June 1, 2016).

Current Tax Payable

Entry #3 Description: Reclassification of the DTL as taxes become due upon receipt of the installment payment on December 31st.

Current Tax Expense

11.6

Entry #4 Description: Amortization of the ASC 810-10-45-8 Asset to income tax expense from the date of the IP sale through December 31st. The ASC 810-10-45-8 Asset is amortized to income tax expense over the IP’s estimated useful life of eight years.

Entry #5 Description: Reclassify the ASC 810-10-45-8 Asset from non-current to current on December 31st.

Sum of the current portion of entries #2, #4, #5 = $19.4M (agrees to unamortized balance included in prepaid expenses and other current assets on page F-53).

Sum of the non-current portion of entries #2 and #5 = $124.6M (agrees to unamortized balance included in other assets on F-25 and F-53).

Explain why a taxes payable account is being reported as an asset.

Company Response:

The taxes payable on inter-company transfers of property asset is the asset account (with a debit balance) created to defer the income tax effect of the IP sale pursuant to ASC 810-10-45-8. Typically, the tax is paid up front, or concurrently, with an intercompany sale of assets, thus a prepaid tax description is normally used. Since the tax in this transaction was not prepaid and instead is payable upon receipt of the eight installment payments, the term “Taxes payable” was considered the most appropriate nomenclature for this account.

LivaNova acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the filing. Staff comments or changes made in response to Staff comments do not foreclose the Commission from taking any action regarding the filing, and LivaNova may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Jun 29, 2017: 10-Q filed Aug 9, 2017 ↗, against the 10-Q filed May 3, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-07-11

Form 10-K/T

2016-11-01 to 2016-11-30 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2016-11-30
Russia and UkraineRevenue
General
SEC asked (1)
We are aware of publicly available information indicating that you are a member of Medical Technology Association Middle East & North Africa (Mecomed), which serves Sudan and Syria. Sudan and Syria are designated by the U.S. Department of State as state sponsors of terrorism, and are subject to U.S. economic sanctions and export controls.
Rest of the question

You do not include disclosure in the Form 10-K/T about contacts with Sudan and Syria. Please describe to us the nature and extent of any past, current and anticipated contacts with Sudan and Syria, whether through direct or indirect arrangements. You should describe any goods, technology or services you have provided into Sudan and Syria, directly or indirectly, and any agreements, arrangements or other contacts you have had with the governments of Sudan and Syria or entities they control.

LIVN answered
Registered in England and Wales

Registered No.

09451374

5 Merchant Square,

North Wharf Road,

London W2 1AY

United Kingdom

T +44 20 37865275 www.livanova.com

A.

Medical Technology Association Middle East & North Africa

LivaNova PLC has been a member of the Medical Technology Association of the Middle East & North Africa (“Mecomed”) since 2015, following the business combination (the “Business Combination”) between Sorin S.p.A. (“Sorin”) and

Cyberonics Inc. (“Cyberonics”). Sorin was a founding member of Mecomed in 2007, along with fellow U.S. and U.K.
Rest of the answer

medical device companies Medtronic (MDT), Smith & Nephew (LSE: SN, NYSE: SNN) and Johnson &

Johnson (JNJ).

Mecomed is a 31-member trade association representing medical device, imaging, and diagnostics companies active in 21 countries across the Middle East and North Africa. The establishment of the trade association was supported by both EUCOMED (now known as MedTech Europe) and AdvaMed, both of which are trade associations representing the industry in Europe and the

United States, respectively. Since the time of its founding, a principal mission of Mecomed has been the advancement of business ethics objectives through the international medical device industry, seeking to apply the standards of conduct required of U.S. and U.K. companies in the business, sales, and marketing operations of intermediaries in the Middle East.

Mecomed has been chosen to receive grant funding from the World Health Organization for the establishment of the region’s first (and currently, to the best of our knowledge, only) independent CVS (Conference Vetting System) in association with Ethical

MedTech. In addition to its close work with Medtech Europe and AdvaMed, Mecomed collaborates in this area with other organizations active in the region, including the US Chamber of Commerce, and various other associations such as ApacMed

(Asia Pacific), SAMED (South Africa), and ARTED (Turkey) to ensure both regulatory and compliance standards are improved within the medical device and related industry sectors.

A LivaNova employee currently acts as a member of the Executive Committee of Mecomed and sponsors the organization’s Compliance

Committee. Participation in these activities and other professional exchanges involving Sudanese and Syrian persons are authorized under economic sanctions maintained by the European Union and Her Majesty’s Treasury in the United Kingdom. They are also permitted under various U.S. sanctions programs administered by the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC).1

See, e.g., 31 C.F.R. Part 583, at General License 1A (authorizing medical associations to conduct professional training seminars related to health in law in Sudan or with Sudanese persons); 31 C.F.R.

§ 542.516(a)(1) (authorizing the export of services to Syria to support the provision of health services); and 31 C.F.R. § 542.526(a) (authorizing U.S. companies and persons to export services to Syria and Syrian persons for the purpose of participating in professional conferences).

B.

Product Supply in Sudan and Syria

LivaNova manufactures and commercializes life-saving and life-sustaining medical device technologies, in three principal areas of business, as follows:

• implantable medical devices for the treatment of epilepsy (Neuromodulation Franchise);

implantable devices for the treatment of cardiac rhythm disorders (CRM Franchise); and implantable medical devices for the repair or replacement of diseased native heart valves, and machines and disposables used in the conduct of major heart surgery resulting from advanced heart disease (Cardiac Surgery

Franchise).

None of these devices has a “dual use.” The devices are used to treat medical conditions such as heart disease, including congenital heart defects, epilepsy, and disorders associated with the rhythm at which the human heart beats.

LivaNova products have been supplied to hospitals in both Sudan and Syria through third-party sales and marketing intermediaries and through humanitarian organizations and charities. Under internal compliance policies that have been in place since 2014, before any sale is conducted or a purchase order accepted, LivaNova requires that each sales and marketing intermediary seeking a contractual relationship with LivaNova (for example, as a third-party distributor) be subject to an approval process. These internal compliance policies and procedures are designed to ensure, amongst other things, compliance with laws maintained by the United States and other relevant governments pertaining to business operations in these countries. For example, they include background checks of the sales and marketing intermediaries and their principals, reputational due diligence, checking and where necessary further investigation regarding any relationships with public officials, and other measures.

Sales of cardiopulmonary and heart valve products from LivaNova’s Cardiac Surgery Franchise described above are made directly to final customer-hospitals, humanitarian or charitable organizations, or to sales and marketing intermediaries that in turn supply hospitals in Sudan and Syria. For the nine-month period ended September 30, 2016, LivaNova’s sales to Sudan and Syria represented approximately one tenth of one percent of LivaNova’s consolidated sales. For the year ended December 31, 2015 (calculated on a pro forma basis to give effect to the Business Combination), sales of these products to Sudan and Syria represented approximately one tenth of one percent of LivaNova’s consolidated sales. For each of the fiscal years ended December 31, 2014 and 2013, sales of these products to Sudan and Syria also represented approximately one tenth of one percent of Sorin’s consolidated sales.

Sales of these products prior to October 19, 2015, the closing date of the Business Combination, occurred only through Sorin and its subsidiaries. Cyberonics did not conduct any sales in Sudan or

Syria during these periods. No sales of products to these countries from either the CRM Franchise or of epilepsy products from the Neuromodulation Franchise occurred during these periods, or to date in 2016.

Prior to the Business Combination, neither Sorin nor Cyberonics held a direct presence or investment in either country. LivaNova does not currently have a direct presence in either country, operating only through humanitarian and charitable organizations or sales and marketing intermediaries, and holds no direct or indirect investments, assets or liabilities in these countries. The current business strategy of LivaNova does not include any plans to open a direct presence in either country or to hold any assets or liabilities or any form of direct or indirect investment in either country.

Read in the reply
General
SEC asked (2)
Please discuss the materiality of any contacts with Sudan and Syria you describe in response to the comment above, and whether the contacts constitute a material investment risk for your security holders. You should address materiality in quantitative terms, including the approximate dollar amounts of any revenues, assets and liabilities associated with Sudan and Syria for the last three fiscal years and the
Rest of the question

subsequent interim period. Also, address materiality in terms of qualitative factors that a reasonable investor would deem important in making an investment decision, including the potential impact of corporate activities upon a company’s reputation and share value. Various state and municipal governments, universities and other investors have proposed or adopted divestment or similar initiatives regarding investment in companies that do business with U.S.-designated state sponsors of terrorism. You should address the potential impact of the investor sentiment evidenced by such actions directed toward companies that have operations associated with Sudan and Syria.

LIVN answered
Based on an assessment of both quantitative and qualitative factors, including the quantitative factors discussed above, LivaNova believes that its operations in Sudan and Syria are not material to LivaNova and do not constitute a material investment risk to our security holders. In assessing materiality of such operations, we have considered materiality based on quantitative factors as well as qualitative factors that a reasonable investor would deem important in making an investment decision in LivaNova securities, including the potential impact on LivaNova’s reputation and share value.

As
Rest of the answer

these products are life-saving or life-sustaining devices for patients in advanced disease states, are used in the Operating Theatres for only those reasons, and are often provided through humanitarian efforts, we do not believe that continued supply of these devices will negatively impact LivaNova reputationally.

* *

LivaNova acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the filing; Staff comments or changes made in response to Staff comments do not foreclose the Commission from taking any action regarding the filing; and LivaNova may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: request for more time, Nov 15, 2016, closing letter, 2016-11-30

Form S-4

2015-05-15 to 2015-08-18 · 35 questions · 3 letters from the SEC, 3 from the company
No closing letter
CybersecurityResults discussion (MD&A)Executive payAcquisitionsNon-GAAP measuresRevenueIncome taxesRisk factors
Structure of the Transaction, page 23
SEC asked (1)
Please expand to discuss briefly the advantages and disadvantages of the chosen structure of the transaction.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 23-24.
Read in the reply
Treatment of Cyberonics Equity Awards, page 27
SEC asked (2)
Please revise to disclose the number of shares that will be issuable pursuant to the accelerated vesting of Cyberonics stock options, restricted stock, and restricted stock units. Also disclose the number of shares that will be issued pursuant to the cash-out of Cyberonics stock options granted prior to January 1, 2013.
Rest of the question

To the extent the total number issuable cannot be determined at this time, please provide an estimate based on recent available information and indicate the assumptions used to calculate the estimate.

LIVN answered
In response to the Staff’s comment, we have revised the disclosure on pages 254-255 in the section entitled “The Merger

Agreement—Treatment of Cyberonics Equity Awards” to include an estimate of the total number of shares that will be issuable pursuant to the Cyberonics equity awards. We have also revised the above-referenced disclosure on page 28 to include a cross-reference to such section.
Read in the reply
Cyberonics Reasons for the Mergers, page 29
SEC asked (3)
Revise to explain briefly the basis for your expectations regarding the potential strategic benefits. Also quantify these expectations where possible.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 29-30. As discussed further in our response to Comment No. 20 from the Staff, the amount of tax savings expected to result from the transaction was not quantified by Cyberonics management or otherwise in connection with the Cyberonics board’s consideration of the business combination transaction with Sorin.
Read in the reply
Interests of Certain Persons in the Merger, page 34
SEC asked (4)
Please quantify, for each director and named executive officer of Cyberonics, the benefits that they will receive as a result of the vesting and settlement of stock options, restricted stock and restricted stock units, the change in control severance plan benefits, retention plan awards, potential excise tax reimbursement, and any other amounts payable in connection with the transaction.
LIVN answered
We respectfully submit that the requested quantification in the section entitled “Summary” of the Amended Registration

Statement is not legally required and would be confusing without the more detailed context provided in the section entitled “Interests of Certain Persons in the Mergers”. In response to the Staff’s comment, we have revised the above-referenced disclosure on page 35 to include a cross-reference to the section entitled “Interests of Certain Persons in the Mergers”, in addition to the section entitled “Golden Parachute Compensation”, where the requested quantification is
Rest of the answer

provided.

Read in the reply
Holdco ordinary shares to be received... will have rights different, page 57
SEC asked (5)
We note your discussion of the differences in rights that Sand Holdco holders will have compared to Cyberonics shareholders includes a reference to shareholder suits. Please highlight in a separate caption the risk arising from Section 49 of Sand Holdco’s articles that provides for exclusive jurisdiction in England and Wales.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on page 60.
Read in the reply
Selected Historical Consolidated Financial Data for Sorin, page 84
SEC asked (6)
Please revise your presentation of basic and diluted earnings per ordinary share presented on this page and throughout the filing, including the consolidated income statement on page F-5, to round to the nearest cent so as not to imply a greater degree of precision than exists.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 87-88, 111, F-45, and F-130.
Read in the reply
Unaudited Pro Forma Condensed Combined Financial Information, page 87
SEC asked (7)
We note that you are accounting for the mergers between Cyberonics, Sorin and Holdco as a “reverse acquisition” pursuant to which Cyberonics will be considered the acquiring entity for accounting purposes in accordance with U.S. GAAP.
Rest of the question

Please provide us with specific details of your analysis of the guidance at FASB ASC Topic 805-10-55 paragraphs 10 through 15 for this transaction in order to further explain how you determined that Cyberonics is the accounting acquirer under U.S. GAAP. Please also revise this section of the filing to provide expanded disclosures as to how you determined Cyberonics is the acquiring entity.

LIVN answered
The following is a discussion of the proposed transaction under Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic ASC 805, Business Combinations, guided by applicable sections in ASC 805-10-55 paragraphs 10-15 with commentary in italics and concluding with the determination of Cyberonics as the accounting acquirer.

Discussion of ASC 805 – Initial Considerations

ASC 805-10-55-12 provides the following considerations for determining the accounting acquirer:

55-12 In a business combination effected primarily by exchanging equity interests, the acquirer
Rest of the answer

usually is the entity that issues its equity interests. However, in some business combinations, commonly called reverse acquisitions, the issuing entity is the acquiree. Subtopic 805-40 provides guidance on accounting for reverse acquisitions. Other pertinent facts and circumstances also shall be considered in identifying the acquirer in a business combination effected by exchanging equity interests, including the following:

a.

The relative voting rights in the combined entity after the business combination. The acquirer usually is the combining entity whose owners as a group retain or receive the largest portion of the voting rights in the combined entity. In determining which group of owners retains or receives the largest portion of the voting rights, an entity shall consider the existence of any unusual or special voting arrangements and options, warrants or convertible securities.

Cyberonics stockholders will receive approximately 54% of the shares of Holdco pursuant to the ultimate exchange ratio, which has been determined, thereby granting Cyberonics the largest portion of voting rights in Holdco. Unusual or special voting arrangements and options, warrants, and convertible securities do not apply. Accordingly, the parties believe that this fact pattern supports the identification of Cyberonics as the accounting acquirer.

b.

The existence of a large minority voting interest in the combined entity if no other owner or organized group of owners has a significant voting interest. The acquirer usually is the combining entity whose single owner or organized group of owners holds the largest minority voting interest in the combined entity.

Cyberonics’s largest stockholder will hold approximately 5.5% of the voting interest in Holdco and will not have any special shareholders’ rights or representation on the board of Holdco. Sorin’s two largest shareholders, which are under common control, will hold approximately 11.7% of the voting interest in Holdco, and the two indirect owners of those shareholders each obtained and exercised the right to designate one of the four allotted seats on the board of Holdco that Sorin will have the right to designate. However, this right does not alter the 4-4-1 composition of the board of Holdco that is discussed further below. Neither these Sorin shareholders nor their indirect owners will have any special shareholders’ rights after closing with respect to Holdco or the Holdco board. Accordingly, the parties do not believe that this fact pattern decisively supports the identification of either Cyberonics or Sorin as the accounting acquirer.

c.

The composition of the governing body of the combined entity. The acquirer usually is the combining entity whose owners have the ability to elect or appoint or to remove a majority of the members of the governing body of the combined entity.

The board of Holdco will consist of nine directors, consisting of four directors designated by

Cyberonics, four directors designated by Sorin, and one member mutually agreed to by Cyberonics and Sorin. The preliminary structure contemplates that this division of the right to designate the Holdco directors will remain in place for approximately eighteen to twenty-one months. The term of the current Holdco directors and the subsequent election / appointment process for the future terms of Holdco directors have yet to be decided. However, the parties do not expect that either former Cyberonics stockholders or former Sorin shareholders will receive special or preferential rights to appoint Holdco directors, or that there will be any tie-breaking privileges. In addition, if a Holdco director were to resign from the board of Holdco during the initial period, then the original party that designated the director would be entitled to replace that director with a person of its designation. If the neutral director were to resign from the board of Holdco, then a new independent director would be designated by representatives of the parties.

The role of the individual Holdco directors and their committee assignments have not yet been decided, except that the Chair of the Audit Committee and the Compensation Committee will be designated from among the Holdco directors to be designated by Cyberonics, as discussed in the Amended Registration

Statement. While Cyberonics will designate the chair of the board of Holdco, who will be the current chief executive officer of Cyberonics, the intention of the parties is to create equal representation of Cyberonics and Sorin on the board of Holdco and to have that structure remain in place for more than two years. Accordingly, the parties do not believe that this fact pattern decisively supports the identification of either Cyberonics or Sorin as the accounting acquirer.

d.

The composition of the senior management of the combined entity. The acquirer usually is the combining entity whose former senior management dominates the management of the combined entity.

The chief executive officer of Holdco will be the current chief executive officer of Sorin. In addition, the combined business will be organized into three business units and an Intercontinental group. The two legacy Sorin business units (Cardiac Surgery and Cardiac Rhythm Management) and the Intercontinental group will be led by current Sorin employees, while a Cyberonics employee will lead the third business unit (Neuromodulation). In addition, Sorin employees will have three of the four positions on the combined business’s executive leadership team, with Cyberonics having one position. Sorin and Cyberonics have also begun a joint search for the chief financial officer of the combined business, with Cyberonics’ chief financial officer serving as interim chief financial officer should the position not be filled prior to closing. Finally, as discussed above, the chair of the board of Holdco will be the current chief executive officer of Cyberonics.

While there is some weighting towards

Sorin senior management attributable to the legacy business units of each company, the parties do not believe that the fact pattern described above supports the guidance that former Sorin senior management “dominates” the management of the combined business. Accordingly, the parties do not believe that this fact pattern decisively supports the identification of either Cyberonics or Sorin as the accounting acquirer.

e.

The terms of the exchange of equity interests. The acquirer usually is the combining entity that pays a premium over the precombination fair value of the equity interests of the other combining entity or entities.

For Sorin shareholders, the exchange ratio implies a per share valuation of Sorin that represents approximately 14.2 percent premium to Sorin’s closing share price on February 25, 2015, the last trading day prior to the public announcement of Sorin and Cyberonics entering into the letter of intent. Accordingly, the parties believe that the exchange ratio, which results in the payment of a premium to Sorin shareholders, supports the identification of Cyberonics as the accounting acquirer.

Discussion of ASC 805 – Additional Considerations

As a final part of the parties’ overall analysis, the parties note that ASC 805 provides for additional considerations when determining the accounting acquirer in ASC 805-10-55-13 through 55-14. These considerations are as follows:

55-13 The acquirer usually is the combining entity whose relative size (measured in, for example, assets, revenues or earnings) is significantly larger than that of the other combining entity or entities.

Sorin is significantly larger than Cyberonics with respect to revenues and assets in the historical periods. However, Cyberonics has a greater market capitalization, free cash flow, profit before tax and net income when the financial statements for both companies are placed on a US GAAP basis. Neither entity has convertible securities that would influence the manner in which market capitalization is computed, which is calculated on a fully diluted basis assuming all stock awards currently outstanding vest. Accordingly, the parties do not believe that this fact pattern decisively supports the identification of either

Cyberonics or Sorin as the accounting acquirer.

55-14 In a business combination involving more than two entities, determining the acquirer shall include a consideration of, among other things, which of the combining entities initiated the combination, as well as the relative size of the combining entities, as discussed in the preceding paragraph.

In connection with its consideration of a potential joint venture, Cyberonics and its financial advisor identified Sorin as a potential joint venture partner in mid-2013, and Cyberonics’ financial advisor facilitated a meeting in July 2014 between Cyberonics and Sorin to discuss a joint venture between the two parties. During the course of discussions between the parties that followed this initial meeting, the parties determined that it was in their respective best interests to explore the possibility of a business combination between the two parties. While Cyberonics’ financial advisor did initiate the discussions with Sorin, the parties do not believe it is clear that Cyberonics “initiated the combination” because the discussions from the initial meeting forward were bilateral and collaborative. Accordingly, the parties do not believe that this fact pattern decisively supports the identification of either Cyberonics or Sorin as the accounting acquirer.

Conclusion

FASB ASC Topic 805-10-55 paragraphs 10 through 15 provide guidance on identifying the acquirer in a business combination. An analysis of this guidance relative to the specific facts and circumstances of the business combination results in the parties’ determination that Cyberonics is appropriately identified as the accounting acquirer. Facts in support of this determination are:

• the larger portion of the voting rights to be held by the former Cyberonics stockholders, which is approximately 54%; and the payment of an approximate 14.2% premium to the Sorin shareholders as a result of the exchange ratio.

While the parties do not believe that the other indicators set forth in ASC 805 decisively support the identification of either Cyberonics or Sorin as the accounting acquirer, the parties’ determination of Cyberonics as the accounting acquirer was based on the collective weight of all the evidence. The parties believe that the indicators pointing to Cyberonics as the accounting acquirer outweigh those potentially pointing to Sorin.

Due to the judgment necessary in reaching this conclusion and to provide the reader with additional insight into the parties’ judgment, we have revised the above-referenced disclosure on page 91.

Read in the reply
Note 3. Unaudited Pro Forma Condensed Combined Balance Sheet Adjustments, page 93
SEC asked (8)
Please refer to adjustment (e). We note that you identified intangible assets with acquisition-date fair values of $759 million. Revise the note to describe in more detail how you determined the estimated fair value of these intangible assets.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 99-100.
Read in the reply
Note 5. Adjustments to Sorin Historical Financial Statements to Conform to Cyberonics, page
SEC asked (9)
Please refer to adjustment (a) and (b) that relate to reconciling Sorin’s December 31, 2014 retained earnings to conform its historical IFRS retained earnings at that date to GAAP. Please revise this note to include additional details in order to enable the reader to determine the nature of, and reason for, the adjustment as well as how it was calculated.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on page 106.
Read in the reply
Sorin, page 143 · Results of Operations, page 147
SEC asked (10)
We note that on this page, on page 150 and throughout the filing that you present non- GAAP measures including but not limited to EBITDA, Adjusted EBITDA, Adjusted Operating Profit, and Adjusted Net Profit. Please tell us how you considered the reconciliation requirements and disclosure guidance in Item 10(e)(1)-(3) as well as Item 10(e)(5) of Regulation S-K in connection with your presentation of these non-GAAP
Rest of the question

measures.

LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 156, 163 and 171.
Read in the reply
Sorin, page 143 · Results of Operations, page 147
SEC asked (11)
Further to the above, we note that on page 147 that you define “EBITDA” as net profit adjusted for the following: (i) depreciation, amortization and write-downs; (ii) additions to provisions for risks and charges; (iii) restructuring charges and provisions; (iv) financial income (expense); (v) share of loss of investments in associates accounted for using the equity method; and (vi) income taxes.
Rest of the question

“EBITDA” is defined as earnings before interest, taxes, depreciation and amortization. As noted in Question 103.01 of our Non-GAAP Financial Measures C&DI located on our website at http://www.sec.gov/divisions/corpfin/guidance/nongaapinterp.htm, measures that are calculated differently than those described as “EBITDA” in Exchange Act Release No. 47226 should not be characterized as “EBITDA” and their titles should be distinguished from “EBITDA" such as "Adjusted EBITDA.” Please revise the filing to properly label all non-GAAP measures.

LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on page 153.
Read in the reply
Sorin, page 143 · Results of Operations, page 147
SEC asked (12)
We note your explanation on page 147 and page 154 of why Sorin’s net revenue fluctuated from fiscal 2014 as compared to fiscal 2013 and from fiscal 2013 as compared to fiscal 2012. Please revise Management's Discussion and Analysis to quantify the reasons for any material changes in financial statements line item amounts between the dates and periods in the financial statements presented.
Rest of the question

For example, please explain if the changes in your revenues were due to changes in prices, volumes or a combination of both items. For further guidance, please refer to Item 5 of Form 20-F as well as SEC Interpretive Release No. 33-8350.

LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 159-162.
Read in the reply
Background of the Mergers, page 181
SEC asked (13)
We note the reference to the expression of a Party D representative of willingness to discuss a possible acquisition of Cyberonics by Party D. Please expand your disclosure to explain why a potential transaction with Party D was not pursued.
Rest of the question

For instance, we note your disclosure on page 186 that the board concluded that the acquisition was not “likely to result in a transaction creating more stockholder value than a strategic combination with Sorin,” but the basis for this belief is not clear from the disclosure. Please revise accordingly.

LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 202-205.
Read in the reply
Background of the Mergers, page 181
SEC asked (14)
Describe in greater detail the negotiations during the meetings on October 8-9, October 20-22, November 2-3, November 11, and December 16-17, 2014, as well as January 9, January 28-29, 2015, to provide shareholders with an understanding of how, when and why these terms of the proposed transaction evolved.
Rest of the question

For instance, with respect to the exchange ratios and ownership percentages, explain how each was determined and which party or parties proposed the final figures. Provide similar expanded disclosure of the discussions held via telephone on January 12, February 2, February 5, 2015 and other dates where the terms of the transaction were discussed.

LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 202-214.
Read in the reply
Background of the Mergers, page 181
SEC asked (15)
Expand your disclosure of the discussions that occurred between January 22, 2015 and February 6, 2015, as mentioned on page 189, to explain the material issues discussed and the positions taken by those involved in those discussions.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 207-209.
Read in the reply
Opinion of Rothschild as Financial Advisor to Sorin, page 200
SEC asked (16)
Please provide us with copies of the materials prepared by Rothschild and Piper Jaffray in connection with their fairness opinions, including, among other things, any “board books,” drafts of fairness opinions, and any summaries of presentations made to the boards.
LIVN answered
In response to the Staff’s comment, the written, confidential materials (including the board books) prepared by Rothschild S.p.A.

(“Rothschild”) and Piper Jaffray & Co. (“Piper Jaffray”) in connection with their opinions and presented to the boards of Sorin and Cyberonics at the respective meetings described in the

Amended Registration Statement are being provided to the Staff by McGuireWoods LLP, as counsel to

Rothschild, and O’Melveny & Myers LLP, as counsel to Piper Jaffray, under separate cover on a confidential and supplemental basis pursuant to Rule 418 of the Securities Act
Rest of the answer

of

1933, as amended, and Rule 12b-4 under the Securities Exchange Act of 1934, as amended. In accordance with such Rules, such materials are being provided together with a request that these materials be returned promptly following completion of the

Staff’s review thereof. Such materials are not, and will not be, filed with or deemed to be part of the Registration Statement, including any amendments thereto. By separate letter, a request for confidential treatment of these materials pursuant to the provisions of 17 C.F.R. § 200.83 has been made.

Read in the reply
Opinion of Rothschild as Financial Advisor to Sorin, page 200
SEC asked (17)
Please revise to clarify how the “subjective judgments and qualitative analysis” mentioned in the last sentence beginning on page 202 affected the disclosed ranges and values of Rothschild’s financial analyses.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 225-226.
Read in the reply
Summary of Financial Analyses of Rothschild, page 203
SEC asked (18)
Please revise to disclose the criteria Rothschild used to select the companies used in the Selected Public Companies Analyses described on pages 204 and 205 If any companies that met such criteria were excluded from the analyses, please also disclose the reasons for the exclusion.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 224-226.
Read in the reply
Other Factors, page 206
SEC asked (19)
Please expand to disclose how these additional factors were considered and how, based on the specific terms of the transaction, these factors support the conclusion that the exchange ratio is fair to Sorin holders.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on page 227.
Read in the reply
Cyberonics Reasons for the Mergers and Recommendation..., page 208
SEC asked (20)
Please expand your disclosure in the fifth bullet point on page 209 where you discuss the “revenue enhancements and cost-savings and synergy opportunities, including potential tax savings” to quantify these items separately and to explain the bases and assumptions used to calculate the amounts.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on page 230 to quantify the amount of revenue enhancements and cost savings expected to be achieved in the mergers, and the bases and assumptions used to calculate those amounts. Cyberonics management did not quantify the amount of tax savings expected to result from the mergers and the

Cyberonics board did not consider or assign a specific value to such tax savings in arriving at its determination to approve the transaction and to recommend the transaction to Cyberonics’ stockholders.
Rest of the answer

Rather, in arriving at its determination, the Cyberonics board considered as a qualitative factor the potential tax savings that could be obtained by creating a more efficient corporate structure for the combined group in the mergers.

Read in the reply
Representations and Warranties, page 234
SEC asked (21)
We note your disclosure that the representations and warranties contained in the merger agreement were “made for the benefit of the other parties to the merger agreement” and that “the assertions embodied in the representations and warranties are qualified by information in a confidential disclosure letter provided by Cyberonics to Sorin, on the one hand, and in a confidential disclosure letter provided by Sorin to
Rest of the question

Cyberonics, on the other hand, delivered in connection with the execution of the merger agreement.” Because the description and the full merger agreement now appear in a disclosure document, please confirm that you have no additional information that would call into question the accuracy of the information contained in your disclosure.

LIVN answered
In response to the Staff’s comment, the parties have advised us, and we confirm on their behalf, that the parties have no additional information that would call into question the accuracy of the information contained in the Registration Statement.
Read in the reply
Interests of Certain Persons in the Mergers, page 261
SEC asked (22)
Please quantify the number of shares underlying options, restricted stock and restricted stock units that will fully vest upon completion of the merger for each director and named executive officer.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 284-285.
Read in the reply
Interests of Certain Persons in the Mergers, page 261
SEC asked (23)
Please expand your disclosure of the Cyberonics options to be cashed out as described in the penultimate paragraph on page 261 to quantify the total amount expected to be paid out pursuant to this feature and the assumptions that were used in calculating the amount.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on page 284.
Read in the reply
Interests of Certain Persons in the Mergers, page 261
SEC asked (24)
Please revise to provide disclosure with respect to the material terms of employment of those named executive officers and directors of Cyberonics who will be employed at the combined company. Also disclose how those agreements differ from current employment arrangements.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 287.
Read in the reply
Interests of Certain Persons in the Mergers, page 261
SEC asked (25)
Please quantify, on an individual basis, the value of the stock appreciation rights to be awarded to Cyberonics’ directors and named executive officers under the anticipated retention plan described on pages 263 – 264.
LIVN answered
The individual allocations under the anticipated stock appreciation rights retention plan are not known at this time and, accordingly, cannot be quantified. We anticipate determining the allocations closer to the closing of the transactions, and Holdco will file a Current Report on Form 8-K disclosing these values once they have been determined.
Read in the reply
Material United States Federal Income Tax Considerations, page 267
SEC asked (26)
Here and throughout your document, as appropriate, please provide unequivocal disclosure regarding the tax consequences to Cyberonics holders, rather than merely what the tax consequences “generally” are or “should be.” Also, if you are unable to provide unequivocal disclosure, you should disclose why, describing the degree of uncertainty and providing risk factor disclosure setting forth the risks to investors due
Rest of the question

to the uncertainty. For example, we note your disclosure in the second full paragraph on page 269 that the remainder of the discussion assumes that HoldCo will not be treated as a U.S. corporation under Section 7874 of the Internal Revenue Code. Please provide disclosure of the alternative tax treatments.

LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure on pages 296-304.
Read in the reply
Security Ownership of Certain Beneficial Owners and Management, page 331
SEC asked (27)
Please revise the footnotes to the table to identify the natural person or persons who hold or share investment control over the shares held by entities.
LIVN answered
In response to the Staff’s comment, we have revised the above-referenced disclosure in footnote (3) on page 362.
Read in the reply
Index to the Consolidated Financial Statements of Sorin S.P.A. and Subsidiaries, page F-1 · Independent Auditor’s Report, page F-2
SEC asked (28)
We note that this Independent Auditor’s Report does not include an opinion on whether the financial statements comply with IFRS as issued by the IASB. Please amend your filing to either provide an audit report that includes an opinion on whether the financial statements comply with IFRS as issued by the IASB, or to include reconciliations from IFRS to US GAAP. Refer to Item 17(c) of Form 20-F.
LIVN answered
In response to the Staff’s comment, the requested audit report has been included on page F-42.
Read in the reply
Note 39. Impact of Material Non Recurring Events and Transactions, page F-95
SEC asked (29)
We note that you are presenting non-GAAP measures entitled “the financial statement amounts before the impact of material nonrecurring events and transactions” for fiscal 2014, 2013 and 2012. Please tell us your consideration of the guidance in Item 10(e)(1)(ii)(C) and 10(e)(5) of Regulation S-K in connection with your presentation of these non-GAAP measures in the notes to the financial statements.
LIVN answered
Sorin presented the significant non-recurring transactions that affected operating profits for each of the fiscal years of Sorin ended 2014, 2013 and 2012 in the paragraph entitled “the financial statement amounts before the impact of material nonrecurring events and transactions” included in footnote 39 to the audited consolidated financial statements of Sorin, as provided for in Resolution No. 15519 of July 27, 2006 (the “CONSOB Resolution No.
Rest of the answer

15519”) of the Italian Corporations and Securities Exchange Commission (Commissione Nazionale per le Società e la Borsa, or “CONSOB”) after consideration of the guidance in the Commission’s Compliance and Disclosure

Interpretation (CDI) 106.01.

Based on CONSOB Resolution No. 15519, listed companies in Italy are required to clearly report non-recurring material income or charges in the financial statements as well as to separately disclose certain significant income or charges pertaining to either:

infrequent or unusual events and transactions, being identified as non-recurring items under such circumstances; or certain events or transactions that are not considered to be representative of the ordinary course of business.

More specifically, the costs presented in footnote 39 were mainly related to the economic impact of the earthquake and restructuring programs described therein, all of which Sorin considers to fall within the definition of non-recurring set out in CONSOB Resolution No. 15519. Accordingly, we respectfully submit that the presentation of these non-GAAP measures is required to be included in the notes to Sorin’s financial statements. However, in response to the Staff’s comment, we have removed the word “non-recurring” from the footnote.

* * * *

Once you have had time to review these responses to the Staff’s comments, we would appreciate the opportunity to discuss any additional questions or concerns that you may have. Please feel free to contact me by telephone at (212) 906-4616.

Read in the reply
SEC letter of Jun 26, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Unaudited Comparative Per Share Data · Pro Forma Per Share Data, page 111
SEC asked (1)
It does not appear the amounts disclosed in this section agree with or are supported by the data in your pro forma financial statements at pages 93 through 95. Please provide us with the calculation of the amounts presented herein using the data in your pro forma financial statements at pages 93 through 95 and revise the disclosures as necessary.
LIVN answered

No reply letter found.

Security Ownership of Certain Beneficial Owners and Management, page 361
SEC asked (2)
We note your response to prior comment 27; however, the natural person or persons who hold or share investment control over the shares held by the entities referenced in notes 16 through 19 of the table have not been disclosed. Please revise or advise.
LIVN answered

No reply letter found.

Consolidated Financial Statements for the Years Ended December 31, 2014, 2013 and 2012 · Note 39. Impact of Significant Material Transactions, page F-135
SEC asked (3)
We note your response to our prior comment 29, which indicates that CONSOB Resolution No. 15519 requires you to “report non-recurring material income or charges in the financial statements as well as to separately disclose certain significant income or charges pertaining to infrequent or unusual events and transactions.” As this appears to be different from your presentation of a net operating measure that excludes
Rest of the question

significant material transactions (i.e., financial statement amounts before the impact of significant material transactions), please provide us with a detailed explanation of your basis for presenting such a measure based on the specific requirements of the CONSOB. Please provide us with a translated version of the specific CONSOB guidance that you believe requires disclosure of such a measure.

LIVN answered

No reply letter found.

Exhibit 5.1
SEC asked (4)
Refer to paragraph 1.3. The exhibit that you file to satisfy your obligations under Regulation S-K Item 601(b)(5) should be based on all applicable documents, not merely a selected set of documents. Please file a revised opinion of counsel accordingly.
LIVN answered

No reply letter found.

Exhibit 5.1
SEC asked (5)
We note the opinion is addressed to the board of directors solely for their benefit in connection with the registration statement. Please file a revised opinion of counsel that does not limit shareholders’ reliance on the opinion.
LIVN answered

No reply letter found.

Security Ownership of Certain Beneficial Owners and Management, page 358
SEC asked
We note your response to prior comment 2; however, the natural person or persons who hold or share investment control over the shares held by Brown Capital Management, LLC, Renaissance Technologies LLC and The Vanguard Group, Inc. have not been identified. Please revise or advise.
LIVN answered
Instruction 3 of Item 403 of Regulation S-K (“Item 403”) provides that a registrant may “rely upon information set forth in such statements [filed pursuant to Section 13(d) or 13(g) of the Securities Exchange Act of 1934] unless the registrant knows or has reason to believe that such information is not complete or accurate or that a statement or amendment should have been filed and was not.” Holdco respectfully advises the Staff that, in accordance with Instruction 3 of Item 403, in compiling the ownership information required by Item 403, Holdco and Cyberonics have relied on the information
Rest of the answer

in the Schedule 13G/As filed with the Commission by Brown Capital Management, LLC (“Brown Capital”), Renaissance Technologies LLC (“Renaissance”) and The Vanguard Group,

Inc. (“Vanguard”) on February 5, 2015, February 12, 2015 and February 10, 2015, respectively (the “Schedule 13Gs”) and, as of the date of the filing of the Second Amended

Registration Statement and as of the date hereof, neither Holdco nor Cyberonics have reason to believe that such information is not complete or accurate or that a statement or amendment should have been filed by any of those entities and was not.

None of Brown Capital, Renaissance or Vanguard disclosed in their respective Schedule 13Gs the natural person or persons who hold or share investment control over the respective shares of Cyberonics attributed to them therein.

Without the same being described in the Schedule 13Gs, neither Holdco nor Cyberonics would have reason to know, and they do not know, the nature of any “contract, arrangement, understanding, relationship or otherwise” pursuant to which a natural person has voting or investment control over the shares held by Brown Capital,

Renaissance or Vanguard, respectively. None of Brown Capital, Renaissance and Vanguard are affiliated with officers or directors of Holdco or Cyberonics. Information regarding the natural person or persons who hold or share investment control over the shares respectively held by such entities therefore rests peculiarly within the knowledge of persons not affiliated with Holdco and Cyberonics and obtaining such information would involve unreasonable effort and expense on the part of Holdco and

Cyberonics. Holdco has disclosed the ownership information required by Item 403 that is in its and Cyberonics’ possession and that they were able to acquire without unreasonable effort or expense. Accordingly, Holdco respectfully submits that information regarding the natural person or persons who hold or share investment control over the shares of Cyberonics held by Brown Capital, Renaissance and Vanguard may be omitted under Rule 409 under the Securities Act of 1933.

* * * *

We hope that this response adequately addresses the Staff’s comment. Once you have had time to review this response, we would appreciate the opportunity to discuss any additional questions or concerns that you may have. Please feel free to contact me by telephone at (212) 906-4616.

Read in the reply

Also in this review: company letter, Aug 18, 2015

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 17 letters filed since 2015-05-15. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LIVN/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.